I am happy to share our first comprehensive report of the DREAM study outcome just published in the journal JAMA! 🩺 Historically, lung transplantation has not been offered to patients with advanced lung cancer due to concerns over poor oncological outcomes. Our prospective registry study challenges this paradigm for a highly selected group of patients. 🫁 I am incredibly grateful for the entire DREAM team, including @AnkitBharatMD, who worked tirelessly to care for this challenging group of patients while pushing the frontline of medicine forward. 🙏 Here are the key takeaways from our newly published research: 🔍 The Study Design Participants: We evaluated 98 adults with medically refractory, “lung-limited”, stage IV non-small cell lung cancer (NSCLC) experiencing respiratory failure. The Cohorts: 17 patients underwent lung transplantation using a dissemination-minimizing technique, while 81 eligible patients received standard medical management alone due to nonbiologic barriers. We also compared outcomes against 306 adults without cancer who underwent lung transplants. 📈 Promising Survival Outcomes 100% vs 40.8%: The estimated 1-year overall survival was 100% in the lung transplant group compared to just 40.8% for those who received medical management alone, a striking absolute difference of 59.2 percentage points! 📊 Excellent Post-Transplant Success: The 1-year posttransplant survival for stage IV NSCLC patients (100%) was highly favorable, even when compared to transplant recipients without cancer (88.1%). 💡 What This Means For carefully selected patients with medically refractory, lung-limited, stage IV NSCLC, lung transplantation can offer exceptionally favorable early survival compared to traditional medical management alone. While longer-term follow-up and quality-of-life assessments are still needed, these findings open a crucial new door for advanced lung cancer care. 🚪 🔗 Read the full paper here: jamanetwork.com/journals/jama/… #LungCancer #LungTransplant @LurieCancer @NUFeinbergMed @NM_Lung @IASLC @LUNGevity @TheCancerLetter @OncoAlert @oncodaily @JAMAOnc @ASCO @myESMO @ISHLT @ttsorg @TheJHLT @amjtransplant @UNOSNews @SWOG @SupportingSWOG @WarOnCancer @EGFRResisters @ALKPositiveinc @targetcancer @OncodailyLung @ACSNews
